Centessa Pharmaceuticals plc has announced a proposed public offering of $150 million of American Depositary Shares (ADSS), with the intention to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of ADSS. The offering is being managed by Goldman Sachs & Co. LLC, Leerink Partners, Evercore ISI, Guggenheim Securities, and BMO Capital Markets.
The offering is subject to market conditions and other factors, and the company has filed a registration statement on Form S-3 with the Securities and Exchange Commission (SEC) on September 11, 2024, which became automatically effective upon filing.
Centessa Pharmaceuticals plc is a clinical-stage pharmaceutical company with advanced programs including a hemophilia program, an orexin agonist program for the treatment of narcolepsy and other sleep-wake disorders, and an immuno-oncology program focused on their Lockbody® technology platform.
The company's press release also includes a disclaimer stating that it does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. As a result of these announcements, the company's shares have moved 12.5% on the market, and are now trading at a price of $16.99. Check out the company's full 8-K submission here.
